Skip to content
  • About us
  • Products
    • MED
    • OTC
    • HEALTH
    • INNOVATION
    • ECO
    • Product lines
  • R&D+i
    • Pharma & OTC
    • Advanced Therapies
  • Our plants
    • Madrid
    • Valencia
  • Our purpose
  • News
  • Contact
  • About us
  • Products
    • MED
    • OTC
    • HEALTH
    • INNOVATION
    • ECO
    • Product lines
  • R&D+i
    • Pharma & OTC
    • Advanced Therapies
  • Our plants
    • Madrid
    • Valencia
  • Our purpose
  • News
  • Contact

The Evolution Of Flu, Common Cold And The OTC Cough & Cold Market

January 13, 2026

The evolution of flu and common cold: health impact and growth of the OTC Cough & Cold market Every winter,

Read more...

Farmalider Receives the 2025 CIEGE Certificate of Excellence in Business Management and Ranks Above the Average of Certified Companies

December 2, 2025

The CIEGE Certificate, promoted by elEconomista.es and Informa D&B, is based on one of the most rigorous evaluations on the

Read more...

International Collaboration in Biotechnology and Pharmaceutical Innovation: Farmalider Welcomes the Shanghai Delegation

December 2, 2025

Pharmaceutical innovation is global. Yesterday, we had the honor of welcoming the Shanghai Municipal Government Delegation to our Madrid offices,

Read more...

López Bran, the Spanish doctor who could put an end to baldness with stem cells: “In 4 years we could have the therapy.”

October 24, 2025

A stem cell–based therapy has succeeded in regenerating hair in mice with induced androgenetic alopecia. This has been achieved by

Read more...

Is the End of Baldness Near? This Is the Spanish Stem Cell–Based Solution That Has Worked in Mice

October 24, 2025

A ray of hope for people seeking to put an end to alopecia. A study conducted by the Department of

Read more...

Ideeea Tx announces AGAcell, a cell therapy program for alopecia

October 15, 2025

Ideeea Therapeutics has closed a €2.3 million seed funding round to drive the development of advanced therapy medicinal products, following

Read more...

Farmalider Group and MASPV collaborate to drive green energy forward

October 15, 2025

The strategic alliance between Farmalider Group and MASPV will reduce their carbon footprint by 70 tonnes of CO₂ per year,

Read more...
  • Legal Notice
  • Privacy policy
  • Ethical Channel
  • Contact
  • Legal Notice
  • Privacy policy
  • Ethical Channel
  • Contact
Farmacovigilancia

Farmalider© 2026

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}